Clinical trial
ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear…
NCT00056537 · Active Biotech AB, Industry · Completed
Key facts
| NCT number | NCT00056537 |
|---|---|
| Title | ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer |
| Official title | An Open-Label, Phase I, Repeat Dose-Escalation Study of ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer |
| Lead sponsor | Active Biotech AB, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Carcinoma, Renal Cell Carcinoma, Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | ABR-217620 |
| Enrollment | 44 |
| Start date | Apr 1, 2003 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Mar 18, 2003 |
| Last update posted | Aug 27, 2014 |
| Countries | Norway, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: